JP2023521042A5 - - Google Patents

Info

Publication number
JP2023521042A5
JP2023521042A5 JP2022560272A JP2022560272A JP2023521042A5 JP 2023521042 A5 JP2023521042 A5 JP 2023521042A5 JP 2022560272 A JP2022560272 A JP 2022560272A JP 2022560272 A JP2022560272 A JP 2022560272A JP 2023521042 A5 JP2023521042 A5 JP 2023521042A5
Authority
JP
Japan
Prior art keywords
sequence
seq
oligonucleotide
salt
manipulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560272A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521042A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/025639 external-priority patent/WO2021203043A2/en
Publication of JP2023521042A publication Critical patent/JP2023521042A/ja
Publication of JP2023521042A5 publication Critical patent/JP2023521042A5/ja
Pending legal-status Critical Current

Links

JP2022560272A 2020-04-02 2021-04-02 操作されたオリゴヌクレオチドを使用する標的化された阻害 Pending JP2023521042A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063004045P 2020-04-02 2020-04-02
US63/004,045 2020-04-02
PCT/US2021/025639 WO2021203043A2 (en) 2020-04-02 2021-04-02 Targeted inhibition using engineered oligonucleotides

Publications (2)

Publication Number Publication Date
JP2023521042A JP2023521042A (ja) 2023-05-23
JP2023521042A5 true JP2023521042A5 (cg-RX-API-DMAC7.html) 2024-04-15

Family

ID=77927597

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560272A Pending JP2023521042A (ja) 2020-04-02 2021-04-02 操作されたオリゴヌクレオチドを使用する標的化された阻害

Country Status (12)

Country Link
US (5) US20230132602A1 (cg-RX-API-DMAC7.html)
EP (1) EP4127175A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023521042A (cg-RX-API-DMAC7.html)
KR (1) KR20230023612A (cg-RX-API-DMAC7.html)
CN (1) CN116096890A (cg-RX-API-DMAC7.html)
AU (1) AU2021246530A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022019889A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174286A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022015141A2 (cg-RX-API-DMAC7.html)
IL (1) IL296957A (cg-RX-API-DMAC7.html)
MX (1) MX2022012265A (cg-RX-API-DMAC7.html)
WO (1) WO2021203043A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117677698A (zh) 2021-07-14 2024-03-08 米雷楚来股份有限公司 用于神经肌肉障碍的寡核苷酸及其组合物
KR20240125036A (ko) 2021-12-23 2024-08-19 마이레큘, 인크. 폴리뉴클레오타이드의 전달을 위한 조성물
KR20230102595A (ko) * 2021-12-30 2023-07-07 주식회사 이노제닉스 포스파티딜이노시톨 3-키나아제 촉매 소단위 알파 유전자의 3'비번역 부위에 특이적으로 결합하는 핵산 절편 및 그 응용
US20230407302A1 (en) * 2022-02-04 2023-12-21 New York University Novel efficacious microrna-30c analogs reduce apolipoprotein b secretion in human liver cells
CN117402251B (zh) * 2023-12-15 2024-02-23 中国医学科学院基础医学研究所 一种抗小g蛋白rbj的抗体及其应用
US20260159835A1 (en) * 2024-12-05 2026-06-11 Soufflé Therapeutics, Inc. Oligonucleotide-mediated knockdown of dux4

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
CA2524569C (en) 2002-05-03 2013-10-22 Duke University A method of regulating gene expression
US8106180B2 (en) * 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
WO2005017145A1 (ja) 2003-08-13 2005-02-24 Japan Biological Informatics Consortium 機能性rnaが制御する被制御遺伝子の同定・予測方法及びその利用方法
US7795419B2 (en) * 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
US20070099196A1 (en) 2004-12-29 2007-05-03 Sakari Kauppinen Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20090209621A1 (en) 2005-06-03 2009-08-20 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
ITMI20051248A1 (it) 2005-07-01 2007-01-02 Vimar Spa Modem per bus per impianti elettrici civili ed industriali
US8481505B2 (en) 2005-09-12 2013-07-09 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
US8603991B2 (en) 2005-11-18 2013-12-10 Gradalis, Inc. Individualized cancer therapy
CA2634046A1 (en) 2005-12-12 2007-06-21 The University Of North Carolina At Chapel Hill Micrornas that regulate muscle cell proliferation and differentiation
EP2484782B1 (en) 2006-01-05 2015-11-18 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
WO2007143752A2 (en) 2006-06-09 2007-12-13 The Regents Of The University Of California Targets in breast cancer for prognosis or therapy
US20100292299A1 (en) 2006-06-20 2010-11-18 Mendell Joshua T Nucleotide Motifs Providing Localization Elements and Methods of Use
US8114982B2 (en) 2006-12-06 2012-02-14 Albert Einstein College Of Medicine Of Yeshiva University Multi-microRNA methods and compositions
JP2010516249A (ja) 2007-01-17 2010-05-20 ザ・ジョンズ・ホプキンス・ユニバーシティ 腫瘍治療のためのミクロrnaに関する組成物及び方法
WO2009012263A2 (en) * 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
CA2694928A1 (en) 2007-07-31 2009-02-05 Board Of Regents, The University Of Texas System Micro-rnas that control myosin expression and myofiber identity
WO2009075817A1 (en) 2007-12-06 2009-06-18 Minerva Biotechnologies Corporation Method for treating cancer using interference rna
JP2010094122A (ja) 2008-06-12 2010-04-30 Keio Gijuku バイオマーカーとしてのマイクロrnaを用いた頭頸部腫瘍の診断・治療選択
US8729041B2 (en) 2008-12-03 2014-05-20 The Johns Hopkins University Compositions and methods for treating hepatic neoplasia
MA33488B1 (fr) 2009-06-08 2012-08-01 Miragen Therapeutics Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn
US8796238B2 (en) 2009-09-17 2014-08-05 Sigma-Aldrich Co. Llc Short RNA mimetics
US20120302626A1 (en) * 2009-12-04 2012-11-29 Sandeep Dave Microrna and use thereof in identification of b cell malignancies
US8768630B2 (en) * 2010-02-19 2014-07-01 The Regents Of The University Of Michigan miRNA target prediction
CN103154246B (zh) 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
EP3118316A1 (en) 2010-09-02 2017-01-18 Université de Mons Agents useful in treating facioscapulohumeral muscular dystrophy
AU2012212023B9 (en) 2011-02-03 2017-01-12 Mirna Therapeutics, Inc. Synthetic mimics of miR-34
US9222085B2 (en) 2011-02-03 2015-12-29 Mirna Therapeutics, Inc. Synthetic mimics of MIR-124
CA2842798C (en) * 2011-07-25 2021-02-23 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of dux4
WO2013019623A2 (en) 2011-07-29 2013-02-07 Fred Hutchinson Cancer Research Center Methods and compositions for modulating the innate immune response and/or myogenesis in a mammalian subject
EP2763703B1 (en) 2011-10-06 2018-02-14 Miragen Therapeutics, Inc. Control of whole body energy homeostasis by microrna regulation
TWI516267B (zh) 2011-11-07 2016-01-11 臺北榮民總醫院 抑制癌症或腫瘤細胞之類癌幹細胞特性及抗化學及放射治療特性的醫藥組合物
WO2013120038A2 (en) 2012-02-10 2013-08-15 Regents Of The University Of Minnesota Morpholino targeting dux4 for treating fshd
WO2013120497A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
DK2872147T3 (da) * 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
US11293064B2 (en) * 2013-05-02 2022-04-05 Thomas Jefferson University Human miRNAs for use in diagnosis, prognosis, and therapy of human conditions and diseases
US9518300B2 (en) 2014-04-14 2016-12-13 Dana-Farber Cancer Institute, Inc. Composition and method for treating a hematological malignancy
CN106794260B (zh) 2014-04-25 2021-02-23 儿童医疗中心有限公司 治疗血红蛋白病的组合物和方法
US10538763B2 (en) * 2015-01-16 2020-01-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of DUX4
EP3286318A2 (en) 2015-04-22 2018-02-28 Mina Therapeutics Limited Sarna compositions and methods of use
WO2017004243A1 (en) * 2015-06-29 2017-01-05 Caris Science, Inc. Therapeutic oligonucleotides
WO2017007886A2 (en) 2015-07-08 2017-01-12 Idera Pharmaceuticals, Inc. Compositions for inhibiting dux4 gene expression and uses thereof
EP3426781B1 (en) * 2016-03-07 2024-06-26 The United States of America, as represented by The Secretary, Department of Health and Human Services Micrornas and methods of their use
BR112018070249A2 (pt) * 2016-04-02 2019-01-29 Research Institute At Nationwide Children's Hospital sistema promotor de u6 modificada para expressão específica de tecido
EP3684378A4 (en) * 2017-09-19 2021-06-16 Children's National Medical Center GAPMERS AND THEIR USES IN THE TREATMENT OF MUSCLE DYSTROPHY
MA49923A (fr) * 2017-10-02 2020-06-24 Res Inst Nationwide Childrens Hospital Système de déciblage de miarn pour interférence spécifique d'un tissu
US10676744B2 (en) * 2017-10-13 2020-06-09 University Of South Carolina Modulation of adipose tissue macrophage phenotype by use of MicroRNA-30
US11268305B2 (en) 2018-05-17 2022-03-08 Kiekert Ag Latching system for a motor vehicle
WO2020028134A1 (en) * 2018-07-30 2020-02-06 Fred Hutchinson Cancer Research Center Methods and compositions for treating cancer
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US12331293B2 (en) * 2018-11-02 2025-06-17 Biomarin Technologies B.V. Bispecific antisense oligonucleotides for dystrophin exon skipping
TW202104595A (zh) 2019-03-29 2021-02-01 日商田邊三菱製藥股份有限公司 用來調節dux4的表現之化合物、方法及醫藥組成物
JP7627495B2 (ja) 2019-07-12 2025-02-06 学校法人東海大学 DUX4 pre-mRNAのスプライシングを変化させるアンチセンスオリゴヌクレオチド
CN122124274A (zh) 2020-01-10 2026-06-02 达因疗法公司 肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途
TW202144572A (zh) 2020-03-19 2021-12-01 美商亞維代堤生物科學公司 治療臉肩胛肱骨肌肉失養症之組合物及方法
AU2021257213A1 (en) 2020-04-17 2022-11-03 Nevada Research & Innovation Corporation CRISPR-inhibition for facioscapulohumeral muscular dystrophy
GB202009618D0 (en) 2020-06-24 2020-08-05 Ucl Business Ltd Therapeutics for the treatment of FSHD
CN116348139A (zh) 2020-07-23 2023-06-27 达因疗法公司 肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途
AU2021313058A1 (en) 2020-07-23 2023-03-30 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
WO2022043566A1 (en) 2020-08-31 2022-03-03 Merck Patent Gmbh Method and device for manufacturing of solid oral dosage forms
EP4204556A4 (en) 2020-08-31 2024-10-02 Modalis Therapeutics Corporation Method for treating facioscapulohumeral muscular dystrophy (fshd) by targeting dux4 gene
AR123420A1 (es) 2020-09-01 2022-11-30 Ultragenyx Pharmaceutical Inc Inhibidores de dux4 y métodos de uso de estos
AU2021342155A1 (en) 2020-09-11 2023-04-13 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
WO2022056269A1 (en) 2020-09-11 2022-03-17 Arrowhead Pharmaceuticals, Inc. Skeletal muscle delivery platforms and methods of use
JP2022055361A (ja) 2020-09-28 2022-04-07 田辺三菱製薬株式会社 Dux4の発現を調節するための医薬組成物

Similar Documents

Publication Publication Date Title
Fathi Dizaji Strategies to target long non-coding RNAs in cancer treatment: progress and challenges
CN103459598B (zh) Mir-124的合成模拟物
JP2023537798A5 (cg-RX-API-DMAC7.html)
JP7432521B2 (ja) 新規小分子活性化rna
EA015570B1 (ru) Фармацевтическая композиция
CN105899663B (zh) 用于基因表达控制的人工模拟miRNA及其用途
WO2017211999A1 (en) Antisense oligonucleotides for modulation of long noncoding rnas
JP7624221B2 (ja) 一本鎖ポリヌクレオチド
KR20230023612A (ko) 조작된 올리고뉴클레오티드를 사용한 표적화된 억제
CN112513062A (zh) 含有寡聚核苷酸的小细胞肺癌治疗药
EP4444357A1 (en) Arnatar compounds and methods for enhanced cellular uptake
CN118146277A (zh) 一种含有1,2,3-三氮唑结构的GalNAc化合物及其与寡核苷酸缀合方法
CN118001292B (zh) 靶向rna的组合物及其用途
JP6934695B2 (ja) 核酸医薬とその使用
Osman et al. Using an aryl phenanthroimidazole moiety as a conjugated flexible intercalator to improve the hybridization efficiency of a triplex-forming oligonucleotide
US6169176B1 (en) Deoxynucleic alkyl thiourea compounds and uses thereof
KR102897439B1 (ko) 타겟 유전자 발현을 조절할 수 있는 핵산 분자 및 이의 용도
JP7017193B2 (ja) Rna作用抑制剤及びその利用
WO2025119303A1 (en) Abasic modification compound, gene modulating agents and the use thereof
WO2024228398A1 (ja) グアニン四重鎖構造を誘導するための核酸剤
CN118878604A (zh) 磷酯骨架修饰的核苷酸及寡核苷酸
CN121204147A (zh) 靶向rna修饰调控的方法
HK40111629A (en) Threose nucleic acid antisense oligonucleotides and methods thereof
WO1997014708A1 (en) Oligonucleotides containing thiol-substituted nucleoside derivatives and methods of use thereof
CN119351403A (zh) 一种反义寡核苷酸-正义寡核苷酸偶联分子及其应用